A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- A. Eden Evins, M.D., M.P.H.
Massachusetts General Hospital
Principal Investigator - Marc Kaufman, Ph.D.
Mclean Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mclean Hospital, Brain Imaging Center
Belmont, Massachusetts, United States
- Mgh Center for Addiction Medicine
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2007
- Primary completion
- 31 Jul 2012
- Completion
- 31 Jul 2012
- Last update posted
- 18 Sept 2012
- Registered enrollment
- 68
- Registry id
- NCT00538070
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.